Hangzhou Tigermed Consulting plans to raise up to $1.38 billion in its Hong Kong listing, which could make the Chinese clinical trial and research firm the largest healthcare transaction in Asia this year, according to a term sheet.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
